Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference

About this update from Replimune Group, Inc.

[{"type":"text","content":"WOBURN, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Executive Chairman and Director of Replimune, will present and host investor meetings at the Piper Jaffray 31st Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY. The Company is scheduled to present on Thursday, December 5, 2019, at 9:10 a.m. ET.\n About Replimune Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of “oncolytic immune-gene therapies” for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action. For more information, please visit www.replimune.com. Replimune ContactPamela Esposito, Ph.D.Replimune Group [email protected] Investor Inquiries Chris BrinzeyWestwicke, an ICR [email protected] Media InquiriesArleen Goldenberg Verge Scientific [email protected] \n\nSource: Replimune Group Inc","length":3367,"tagName":"div"}]

More updates from Replimune Group, Inc.